Cancer
-
Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading
OCTOBER 17, 2022 – 4 MINUTES READ The activity of four specific genes in the cancer cells seems to…
Read More » -
A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies
Robert A Figlin, MD, FACP1 , Senthil Pazhanisamy, PhD2 1. Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health System, Los Angeles…
Read More » -
2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy
ESMO’22 Special Robert A. Figlin, MD, FACS Cedars Cinai Cancer Center, Los Angeles, CA Correspondence: RAF There was never a…
Read More » -
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors
Grayce N. Selig, MD1 Christopher J. Hoimes, DO,2 Joe Bible, PhD,3 Daniel J. George, MD,2 Michael R. Harrison, MD2 1. Duke University Medical Center…
Read More » -
Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting
. Updated Yasser Ged,1 and Nirmish Singla2,* 1) Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA…
Read More » -
Engineered T-Cell Therapy: The Next Direction for RCC Immuno-oncology?
JJ H. Zhang, MD,1 Neal A. Patel, MD,1 Alexandra Drakaki, MD, PhD,1,2 Allan J. Pantuck, MD1,* 1) Institute of Urologic Oncology, Department of…
Read More » -
Comparison of Papillary Renal Cell Carcinoma Type 1 and Type 2: A Secondary Data Analysis
Melissa Paquin, PhD,1 Tracy Fasolino, PhD, FNP,2 Joe Bible, PhD,3 Mary Beth Steck, PhD,2 Joel Williams, PhD.4 1. Clemson University, Hampton, GA 30228 USA.…
Read More » -
Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma
Robert J Motzer, MD 1, Toni K Choueiri, MD 2, Laurence Albiges, MD, PhD 3,Robert A. Figlin, MD, FACP4 Memorial…
Read More » -
From Gene Discovery to a FDA approval; Belzutifan’s Fascinating Journey at UTSW
Published on: August 21, 2021 A novel kidney cancer drug developed from UT Southwestern Medical Center received approval from the Food…
Read More » -
Keytruda plus Lenvima Combo Received FDA Approval for Advanced Kidney Cancer
August 20, 2021 Frontline Keytruda plus Lenvima for advanced renal cell carcinoma is an effective treatment with life-prolonging benefits, although…
Read More »
